Ratings Theracryf Plc

Equities

EVG

GB00BSVYN304

Market Closed - London S.E. Other stock markets 09:05:18 10/05/2024 pm IST			5-day change	1st Jan Change
0.75 ^GBX	0.00%		0.00%	-53.12%

26/04	Evgen Pharma plc will Change its Ticker to TCF from EVG	CI
26/04	Evgen Pharma plc will Change its Name to TheraCryf plc	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's enterprise value to sales, at 2.1 times its current sales, is high.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
THERACRYF PLC	-53.12%	4.01M	-
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B	B+
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B	B+
ARGENX SE	+1.28%	22.25B	B
BIONTECH SE	-13.14%	22.09B	B+
GENMAB A/S	-7.05%	18.68B	A-
WUXI APPTEC CO., LTD.	-38.36%	17.58B	A-
BEIGENE, LTD.	-10.66%	16.85B	B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B	C+
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes